DSM-265 Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor Treatment of malaria

摘要

Malaria remains a significant threat to human health worldwide with increasingly serious challenges being faced due to emerging drug resistance. DSM-265 is a potent and selective triazolopyrimidine-based inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) and kills drug-resistant malaria parasites in blood and liver by targeting the parasite replication. Created through a collaboration by the University of Texas Southwestern, University of Washington and Monash University, DSM-265 is being developed by the Medicines for Malaria Venture (MMV) in collaboration with Takeda Pharmaceutical and with support from the Global Health Innovative Technology (GHIT) Fund.